Scintigraphic evaluation of malignant melanoma lesions with Tc-99m tetrofosmin

Clinical Nuclear Medicine

Volumn 23, Issue 10, 1998, Pages 683-685

  Alonso, Omar ^a,c   Martinez, Miguel ^a   Mut, Fernando ^a   Bruno, Jose ^a   Delgado, Lucia ^a   Lago, Graciela ^a   Nuñez, Margarita ^a   Bazzano, Carlos ^a   Espasandin, Jose ^b   Touya, Eduardo ^a  

^a UNIVERSITY OF URUGUAY   (Uruguay)

^b National Institute of Oncology   (Uruguay)

^c HOSPITAL DE CLÍNICAS   (Uruguay)

Author keywords

Malignant Melanoma; Radionuclide Imaging; Tc 99m Tetrofosmin

Indexed keywords

TETROFOSMIN TC 99M;

ADULT; ARTICLE; CANCER RECURRENCE; CASE REPORT; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOSCINTIGRAPHY; LYMPH NODE METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; RECURRENT DISEASE; SCINTIGRAPHY; SKIN METASTASIS;

ADULT; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; SKIN NEOPLASMS;

EID: 0031767540     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199810000-00007     Document Type: Article

References (25)

1. Tamaki N, Takahashi N, Kawamoto M, et al: Myocardial tomography using technetium-99m tetrofosmin to evaluate coronary artery disease. J Nucl Med 35:594, 1994.
2. Abdel-Dayem HM, Scott AM, Macapinlac HA, et al: Role of Tl-201 chloride and Tc-99m sestamibi in tumor imaging. In: Freeman LM, ed: Nuclear Medicine Annual. New York, Raven Press, 1994:181-234.
3. Mansi L, Rambaldi PF, Procaccini E, et al: Scintimmamography with technetium-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases. Eur J Nucl Med 23:932, 1996.
4. Lind P, Gallowitsch HJ, Langsteger W, et al: Technetium-99m tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 38:348, 1997.
5. 99mTc-tetrofosmin. Nucl Med Commun 17:577, 1996.
6. Morton D, Wong J, Kirkwood J, et al: Malignant melanoma. In: Holland J, Frei E, Bast Jr R, et al, eds: Cancer Medicine. Malvern, PA: Lea & Febiger, 1993:1793-1824.
7. Berdeaux DH, Moon TE, Meyskens FL: Clinical-biologic patterns of metastatic melanoma and their effects on treatment. Cancer Treat Rep 69:397, 1985.
8. Feggi L, Indelli M, Pansini GC, et al: Immunoscintigraphy in malignant melanoma: A five-year clinical experience. Nucl Med Commun 14:145, 1993.
9. Sergieva S, Goranov K, Piperkova E, et al: Role of radioimmunoscintigraphy and SPECT in the diagnosis of patients with malignant melanoma. Nucl Med Commun 15:168, 1994.
10. Boni R, Huch-Boni RA, Steinert H, et al: Anti-melanoma monoclonal antibody 225.28S immunoscintigraphy in metastatic melanoma. Dermatology 191:119, 1993.
11. Blessing C, Feine U, Geiger L, et al: Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma. Arch Dermatol 131:1394, 1995.
12. Nicholl C, Mohammed A, Hull WE, et al: Pharmacokinetics of iodide-123 IMBA for melanoma imaging. J Nucl Med 38:127, 1997.
13. Hoefnagel CA, Rankin EM, Valdes-Olmos RA, et al: Sensitivity versus specificity in melanoma using iodine-123 iodobenzamide and indium-111 pentetreotide. Eur J Nucl Med 21:587, 1994.
14. Rettenbacher L, Koller J, Galvan J: Detection of cutaneous metastatic melanoma with Tl-201 scintigraphy. Clin Nucl Med 21: 67, 1996.
15. Ryu YH, Chung TS, Lee JD, et al: Detection of malignant melanoma by Tc-99m HMPAO. Clin Nucl Med 20:528, 1995.
16. 99mTc-anti-melanoma antibody: A comparative study. Nucl Med Commun 16:927, 1995.
17. Alonso O, Martinez M, Lago G, et al: Scintigraphic evaluation of invasive cutaneous malignant melanoma with Tc-99m MIBI. Clin Nucl Med 21:557, 1996.
18. 99mTc-sestamibi uptake by malignant melanoma lesions (letter). Nucl Med Commun 17:542, 1996.
19. Alonso O, Martinez M, Lago G, et al: Scintigraphic evaluation of malignant melanoma lesions with Tc-99m MIBI (abstract). J Nucl Med 37:266P, 1996.
20. 99mTc-sestamibi SPECT (single photon emission tomography) during follow-up of malignant melanoma in 17 patients. Eur J Dermatol 6:505, 1996.
21. Platts EA, North TL, Pickett RD, et al: Mechanism of uptake of technetium-tetrofosmin. I: Uptake into isolated adult rat ventricular myocytes and subcellular localization. J Nucl Cardiol 4:317, 1995.
22. Arbab AS, Koizumi K, Toyama K, et al: Uptake of technetium-99m tetrofosmin, technetium-99m MIBI, and thallium-201 in tumor cell lines. J Nucl Med 37:1551, 1996.
23. Ballinger JR, Bannerman J, Boxen I, et al: Technetium-99m tetrofosmin as a substrate for P-glycoprotein: In vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 37:1578, 1996.
24. Chen LB: Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4:155, 1988.
25. Schadendorf D, Herfordt R, Czarnelzki BM: P-glycoprotein expression in primary and metastatic malignant melanoma. Br J Dermatol 132:551, 1995.